Navigation Links
OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation
Date:3/21/2011

HONG KONG, March 21, 2011 /PRNewswire/ -- OrbusNeich today announced that it has filed a lawsuit in the Netherlands against Dr. Pavel Cervinka and Masaryk Hospital in Usti nad Labem, Czech Republic, where Dr. Cervinka is head of the hospital's Cardiology Department. The suit relates to a clinical study conducted at the Masaryk Hospital, in which Dr. Cervinka was the Principal Investigator, which purported to randomly compare OrbusNeich's Genous stent with a bare metal stent for treatment of a class of heart attack patients.  The results of the study reported certain adverse events with the OrbusNeich stent.  However, upon a review of the study by OrbusNeich and independent evaluators, it was revealed that there were many inaccuracies, misrepresentations and inconsistencies in the study, the study methods, and the reporting of the study conclusion.

The lawsuit alleges that Dr. Cervinka and the Masaryk Hospital have committed unlawful acts and asks for an injunction against further presentations or publications of the study.   Additionally, OrbusNeich requests that the court's decision be submitted for publication in the U.S. Journal in which the study was published by Dr. Cervinka and an acknowledgement of the decision also be placed by Dr. Cervinka in the Journal, as well as other remedies.

After the first presentation of the study at the American College of Cardiology in March 2009, in accordance with the practice of proper corporate responsibility and a serious concern for patient welfare, OrbusNeich personnel contacted Dr. Cervinka to discuss the study and investigate the circumstances surrounding the reported adverse events. In response, Dr. Cervinka provided limited information on three patients who experienced a stent thrombosis (blood clot). An independent evaluation of the data relating to those patients revealed procedural complications for all three patients, namely under-expansion, geographic miss and malapposed struts in a
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
2. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
3. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
4. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
5. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
6. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
10. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
11. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... VIEW, Calif., Feb. 10, 2011 ZONARE Medical Systems, ... z.one Ultrasound System to Woodlands Church of Plover, WI, ... the past year, ZONARE has provided six systems to ... and medical missions. Woodlands Church performs annual ...
... AlphaDetail, a leader in global primary market research for ... in revenue in 2010, exceeding $18.5M in annual revenue ... "Our clients have delivered a loud and clear ... get at the heart of their strategic information needs," ...
Cached Medicine Technology:ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 2ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 3AlphaDetail Revenue Soars 30% in 2010 2
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... support cells and immune cells and the role ... development of diseases could open new therapeutic avenues ... conclusion of a review article by scientists from VIB ... . , Prof. Peter Carmeliet: "Consider the review article ... cells has been examined in minute detail for decades ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... Researchers from Montefiore Medical Center and the ... University will present new findings at the Alzheimer,s Association ... 17 in Copenhagen, Denmark. Data from the four abstracts ... cognitive normality to mild cognitive impairment and dementia. The ... , established in 1980 to examine healthy brain aging ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... Nfocus Neuromedical, Inc.,today announced that the company ... and Delivery System. The CardioVasc(TM),Stent-Graft is a minimally ... Lesions (SVGs) from a previous coronary bypass, Vessel,Perforations ... Nfocus to,begin marketing the CardioVasc(TM) Stent-Graft in the ...
... Division becomes newest reseller ... xTag wireless microphone, MAYNARD, Mass., Feb. 12 ... for enhancing collaboration, today announced,that the Dictaphone Healthcare ... xTag Wireless Microphone alongside its Dragon(R),NaturallySpeaking(R) Medical speech ...
... high-end ,infotainment, systems manufacturer to manage global ... manufacturing operations with Visiprise Manufacturing, ... leader in,integrated manufacturing execution (MES) solutions today ... Harman,International, has selected Visiprise Manufacturing as their ...
... TeamStaff, Inc.,(Nasdaq: TSTF ) a national ... today that it is changing the name ... Inc., to TeamStaff,Government Solutions (dba TeamStaff GS)., ... provides medical, office,administration and logistics professionals through ...
... Mich., Feb. 12 Affiliated Computer,Services, Inc. (ACS) ... Healthcare Solutions -- has earned four no. 1 ... Awards, issued by KLAS Enterprises, LLC., The ... Implementation Principal,Financial Implementation Supportive, Staff Augmentation, and Other,Implementation ...
... AMN Healthcare Services,Inc. (NYSE: AHS ), ... Hala Moddelmog, President and Chief Executive Officer,of Susan ... company,s Board of,Directors., "Hala brings valuable experience ... in the global breast cancer movement and,previously, as ...
Cached Medicine News:Health News:Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 3Health News:Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution 2Health News:Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution 3Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:ACS is 'Best in KLAS' for Healthcare Consulting Services 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 3
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
Medicine Products: